2025³â 10¿ù 22ÀÏ(¼ö) - ¸ÞÀÎ ÄÁÆÛ·±½º µÑ°³¯ - ÀϺ» ½Ã°££¨GMT+09:00£©
2025³â 10¿ù 22ÀÏ(¼ö) - ¸ÞÀÎ ÄÁÆÛ·±½º µÑ°³¯
- ÀϺ» ½Ã°££¨GMT+09:00£©
search
08:30 - 08:355ÝÂ
Optimizing Efficiency & Quality Control While Reducing Cost of Manufacturing
Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
Chairperson¡¯s Opening Remarks: Optimizing Efficiency & Quality Control While Reducing Cost of Manufacturing
ÀÇÀå °³È¸»ç : Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
ÀÇÀå °³È¸»ç : Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
- Scott Wheelwright, PhD - Co-Founder and President, BEI
08:30 - 08:355ÝÂ
Global Regulatory Alignment and Harmonization
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
Chairperson¡¯s Welcome and Opening Remarks: Global Regulatory Alignment and Harmonization
ÀÇÀåÀÇ È¯¿µ ¹× °³È¸»ç : ±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
ÀÇÀåÀÇ È¯¿µ ¹× °³È¸»ç : ±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
08:35 - 09:0530ÝÂ
Optimizing Efficiency & Quality Control While Reducing Cost of Manufacturing
Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
Accelerating Process Development and Reducing Manufacturing Cost for Biologics: A Case Study
¹ÙÀÌ¿À·ÎÁ÷½º¿¡¼ ÇÁ·Î¼¼½º °³¹ßÀÇ °¡¼Ó°ú Á¦Á¶ ºñ¿ëÀÇ »è°¨ : »ç·Ê ¿¬±¸
¹ÙÀÌ¿À·ÎÁ÷½º¿¡¼ ÇÁ·Î¼¼½º °³¹ßÀÇ °¡¼Ó°ú Á¦Á¶ ºñ¿ëÀÇ »è°¨ : »ç·Ê ¿¬±¸
08:35 - 09:0530ÝÂ
Global Regulatory Alignment and Harmonization
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
Early Development of a Global Regulatory Strategy
±Û·Î¹ú ±ÔÁ¦ Àü·«ÀÇ Á¶±â Ã¥Á¤
±Û·Î¹ú ±ÔÁ¦ Àü·«ÀÇ Á¶±â Ã¥Á¤
- Jack Wong - CEO and Founder, Asia Regulatory Professionals Association (ARPA)
09:05 - 09:3530ÝÂ
Optimizing Efficiency & Quality Control While Reducing Cost of Manufacturing
Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
Streamline Biologics Process Characterization and Control Strategy Development
¹ÙÀÌ¿À·ÎÁ÷½ºÀÇ ÇÁ·Î¼¼½º Ư¼º Æò°¡¿Í °ü¸® Àü·« °³¹ßÀÇ ÇÕ¸®È
¹ÙÀÌ¿À·ÎÁ÷½ºÀÇ ÇÁ·Î¼¼½º Ư¼º Æò°¡¿Í °ü¸® Àü·« °³¹ßÀÇ ÇÕ¸®È
- Sadettin Ozturk, Ph.D. - Chief Technology Officer, STRM.BIO
09:05 - 09:3530ÝÂ
Global Regulatory Alignment and Harmonization
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
Strategies for Meeting U.S. FDA Cell Therapy IND Requirements: A Case Study Approach
¹Ì±¹ FDAÀÇ ¼¼Æ÷Ä¡·á IND ¿ä°ÇÀ» ÃæÁ·ÇÏ´Â Àü·« : »ç·Ê ¿¬±¸ ¾îÇÁ·ÎÄ¡
¹Ì±¹ FDAÀÇ ¼¼Æ÷Ä¡·á IND ¿ä°ÇÀ» ÃæÁ·ÇÏ´Â Àü·« : »ç·Ê ¿¬±¸ ¾îÇÁ·ÎÄ¡
- Minghua Liu - CMC Consultant, Regulatory Affairs, Eliquent Life Sciences
09:35 - 10:0530ÝÂ
Optimizing Efficiency & Quality Control While Reducing Cost of Manufacturing
Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
Á¦Á¶ ºñ¿ëÀ» »è°¨ÇÏ¸é¼ È¿À²°ú ǰÁú°ü¸®¸¦ ÃÖÀûÈ
Optimizing Process Development and Clinical Production Efficiency with Continuous Improvement Projects
Áö¼ÓÀû °³¼± ÇÁ·ÎÁ§Æ®¿¡ ÀÇÇÑ ÇÁ·Î¼¼½º °³¹ß°ú ÀÓ»ó »ý»ê È¿À²ÀÇ ÃÖÀûÈ
Áö¼ÓÀû °³¼± ÇÁ·ÎÁ§Æ®¿¡ ÀÇÇÑ ÇÁ·Î¼¼½º °³¹ß°ú ÀÓ»ó »ý»ê È¿À²ÀÇ ÃÖÀûÈ
09:35 - 10:0530ÝÂ
Global Regulatory Alignment and Harmonization
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
How Startups and Researchers Can Collaborate with Government and Support Organizations
½ºÅ¸Æ®¾÷ ±â¾÷°ú ¿¬±¸ÀÚ°¡ Á¤ºÎ ¹× Áö¿ø ´Üü¿Í Á¦ÈÞÇÏ´Â ¹æ¹ý
½ºÅ¸Æ®¾÷ ±â¾÷°ú ¿¬±¸ÀÚ°¡ Á¤ºÎ ¹× Áö¿ø ´Üü¿Í Á¦ÈÞÇÏ´Â ¹æ¹ý
- Maggie Lo - Senior VP, Life and Health Technology, Office for Attracting Strategic Enterprises
10:05 - 10:4540ÝÂ
Networking Refreshment Break in Poster/Exhibit Hall
Æ÷½ºÅÍ/Àü½ÃȦ ³×Æ®¿öÅ· ¸®ÇÁ·¹½Ã ºê·¹ÀÌÅ©
Æ÷½ºÅÍ/Àü½ÃȦ ³×Æ®¿öÅ· ¸®ÇÁ·¹½Ã ºê·¹ÀÌÅ©
10:45 - 11:1530ÝÂ
Adopting AI, Automation, and Advanced Analytics
AI¡¤ÀÚµ¿È¡¤Ã·´Ü ¾Ö³Î¸®Æ½½ºÀÇ µµÀÔ
AI¡¤ÀÚµ¿È¡¤Ã·´Ü ¾Ö³Î¸®Æ½½ºÀÇ µµÀÔ
Leveraging AI And Advanced Analytics to Enhance Bioprocess Efficiency
AI¡¤Ã·´Ü ¾Ö³Î¸®Æ½½º¸¦ Ȱ¿ëÇÑ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º È¿À²ÀÇ Çâ»ó
AI¡¤Ã·´Ü ¾Ö³Î¸®Æ½½º¸¦ Ȱ¿ëÇÑ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º È¿À²ÀÇ Çâ»ó
- Niki Wong - Director, Global Technical Operations CMC, AbbVie Operations Singapore Pte Ltd (pending)
10:45 - 11:1530ÝÂ
Global Regulatory Alignment and Harmonization
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
Navigating China¡¯s Evolving Regulatory Landscape and Bridging it with Global Development
Áß±¹ÀÇ ÁøÈÇÏ´Â ±ÔÁ¦ »óȲ¿¡ ´ëÇÑ ´ëÀÀ°ú ±Û·Î¹ú °³¹ß°úÀÇ ¿¬°á
Áß±¹ÀÇ ÁøÈÇÏ´Â ±ÔÁ¦ »óȲ¿¡ ´ëÇÑ ´ëÀÀ°ú ±Û·Î¹ú °³¹ß°úÀÇ ¿¬°á
- Wendy Yan - MBA, former SVP & Global Head of Regulatory Affairs, BeiGene
11:15 - 11:4530ÝÂ
Adopting AI, Automation, and Advanced Analytics
AI¡¤ÀÚµ¿È¡¤Ã·´Ü ¾Ö³Î¸®Æ½½ºÀÇ µµÀÔ
AI¡¤ÀÚµ¿È¡¤Ã·´Ü ¾Ö³Î¸®Æ½½ºÀÇ µµÀÔ
AI-Driven Bioprocessing: Innovations in Upstream and Downstream Development
AI µå¸®ºì ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì : ¾÷½ºÆ®¸²¡¤´Ù¿î½ºÆ®¸²ÀÇ °³¹ß¿¡¼ÀÇ Çõ½Å
AI µå¸®ºì ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì : ¾÷½ºÆ®¸²¡¤´Ù¿î½ºÆ®¸²ÀÇ °³¹ß¿¡¼ÀÇ Çõ½Å
- Mark Duerkop - Chief Executive Officer, Novasign, Austria
11:15 - 11:4530ÝÂ
Global Regulatory Alignment and Harmonization
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
Ensuring Quality and Safety for Cell & Gene Therapy Products Under Evolving Guidelines
ÁøÈÇÏ´Â °¡À̵å¶óÀο¡ ±â¹ÝÇÑ ¼¼Æ÷Ä¡·á¡¤À¯ÀüÀÚ Ä¡·á Á¦Ç°ÀÇ Ç°Áú°ú ¾ÈÀü¼º È®º¸
ÁøÈÇÏ´Â °¡À̵å¶óÀο¡ ±â¹ÝÇÑ ¼¼Æ÷Ä¡·á¡¤À¯ÀüÀÚ Ä¡·á Á¦Ç°ÀÇ Ç°Áú°ú ¾ÈÀü¼º È®º¸
11:45 - 12:1530ÝÂ
Adopting AI, Automation, and Advanced Analytics
AI¡¤ÀÚµ¿È¡¤Ã·´Ü ¾Ö³Î¸®Æ½½ºÀÇ µµÀÔ
AI¡¤ÀÚµ¿È¡¤Ã·´Ü ¾Ö³Î¸®Æ½½ºÀÇ µµÀÔ
The Future of Biopharma: AI-Enabled Automation and Continuous Processing for Faster, Smarter Production
¹ÙÀÌ¿ÀÆÄ¸¶ÀÇ ¹Ì·¡ : ½Å¼Ó¡¤½º¸¶Æ® »ý»ê¿¡ ´ëÇÑ AI ´ëÀÀÀÇ ÀÚµ¿È¿Í ¿¬¼Ó ÇÁ·Î¼¼½Ì
¹ÙÀÌ¿ÀÆÄ¸¶ÀÇ ¹Ì·¡ : ½Å¼Ó¡¤½º¸¶Æ® »ý»ê¿¡ ´ëÇÑ AI ´ëÀÀÀÇ ÀÚµ¿È¿Í ¿¬¼Ó ÇÁ·Î¼¼½Ì
- Mrinal Bachute - Head Industry Connect, Associate Professor, Symbiosis Institute of Technology, Symbiosis International University
11:45 - 12:1530ÝÂ
Global Regulatory Alignment and Harmonization
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
Global Regulatory Strategy, Policy Harmonization, and Bridging Japan¡¯s Requirements with Global Development Programs
±Û·Î¹ú ±ÔÁ¦ Àü·«, Á¤Ã¥ Á¶È, ÀϺ»ÀÇ ¿ä°Ç°ú ±Û·Î¹ú °³¹ß ÇÁ·Î±×·¥ÀÇ ¿¬°á
±Û·Î¹ú ±ÔÁ¦ Àü·«, Á¤Ã¥ Á¶È, ÀϺ»ÀÇ ¿ä°Ç°ú ±Û·Î¹ú °³¹ß ÇÁ·Î±×·¥ÀÇ ¿¬°á
12:15 - 12:4530ÝÂ
Adopting AI, Automation, and Advanced Analytics
AI¡¤ÀÚµ¿È¡¤Ã·´Ü ¾Ö³Î¸®Æ½½ºÀÇ µµÀÔ
AI¡¤ÀÚµ¿È¡¤Ã·´Ü ¾Ö³Î¸®Æ½½ºÀÇ µµÀÔ
Scientific Track Presentation
°úÇÐ Æ®·¢ ÇÁ·¹Á¨Å×À̼Ç
°úÇÐ Æ®·¢ ÇÁ·¹Á¨Å×À̼Ç
12:15 - 12:4530ÝÂ
Global Regulatory Alignment and Harmonization
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
±Û·Î¹ú ±ÔÁ¦ Á¶Á¤°ú Á¶È
Scientific Track Presentation
°úÇÐ Æ®·¢ ÇÁ·¹Á¨Å×À̼Ç
°úÇÐ Æ®·¢ ÇÁ·¹Á¨Å×À̼Ç
12:45 - 13:5570ÝÂ
Luncheon in the Poster/Exhibit Hall
Æ÷½ºÅÍ/Àü½ÃȦ ¿ÀÂùȸ
Æ÷½ºÅÍ/Àü½ÃȦ ¿ÀÂùȸ
13:55 - 14:005ÝÂ
Achievements in Intensified, Continuous, and Sustainable Bioprocessing
°È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
°È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
Chairperson¡¯s Remarks: Achievements in Intensified, Continuous, and Sustainable Bioprocessing
ÀÇÀå Àλç : °È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
ÀÇÀå Àλç : °È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
13:55 - 14:005ÝÂ
Regulatory & CMC Strategies for Emerging Modalities
½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
Chairperson¡¯s Remarks: Regulatory & CMC Strategies for Emerging Modalities
ÀÇÀå Àλç : ½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
ÀÇÀå Àλç : ½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
14:00 - 14:3030ÝÂ
Achievements in Intensified, Continuous, and Sustainable Bioprocessing
°È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
°È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
Enabling Robust Continuous Biomanufacturing Using Digital Twins
µðÁöÅÐ Æ®À©À» ÀÌ¿ëÇÑ °ß°íÇÑ ¿¬¼Ó ¹ÙÀÌ¿ÀÁ¦Á¶ÀÇ ½ÇÇö
µðÁöÅÐ Æ®À©À» ÀÌ¿ëÇÑ °ß°íÇÑ ¿¬¼Ó ¹ÙÀÌ¿ÀÁ¦Á¶ÀÇ ½ÇÇö
- Christoph Herwig - Founder, Lisalis GmbH
14:00 - 14:3030ÝÂ
Regulatory & CMC Strategies for Emerging Modalities
½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
Future Direction on CMC of Next Generation ADCs
Â÷¼¼´ë ADCÀÇ CMC¿¡ ´ëÇÑ ÇâÈÄ ¹æÇ⼺
Â÷¼¼´ë ADCÀÇ CMC¿¡ ´ëÇÑ ÇâÈÄ ¹æÇ⼺
- Gang Qin, PhD - President, GeneQuantum Healthcare (Suzhou) Co., Ltd.
14:30 - 15:0030ÝÂ
Achievements in Intensified, Continuous, and Sustainable Bioprocessing
°È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
°È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
Sustainability Considerations in Regards to Geographical and Process Intensification
Áö¸®Àû¡¤ÇÁ·Î¼¼½º °È¿¡ °üÇÑ Áö¼Ó°¡´É¼ºÀÇ °í·Á »çÇ×
Áö¸®Àû¡¤ÇÁ·Î¼¼½º °È¿¡ °üÇÑ Áö¼Ó°¡´É¼ºÀÇ °í·Á »çÇ×
- Yuki Abe, Ph.D., - Director, BioPharm Services Ltd.
14:30 - 15:0030ÝÂ
Regulatory & CMC Strategies for Emerging Modalities
½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
Implementing Continuous Processing for Novel Modalities from Small to Large Scale - Overcoming Current and Planning for Future Challenges
¼Ò±Ô¸ðºÎÅÍ ´ë±Ô¸ð±îÁö ½Å±Ô ¸ð´Þ¸®Æ¼¿¡¼ ¿¬¼Ó ÇÁ·Î¼¼½ºÀÇ µµÀÔ - ÇöÀçÀÇ °úÁ¦ ±Øº¹°ú ÇâÈÄ °èȹ
¼Ò±Ô¸ðºÎÅÍ ´ë±Ô¸ð±îÁö ½Å±Ô ¸ð´Þ¸®Æ¼¿¡¼ ¿¬¼Ó ÇÁ·Î¼¼½ºÀÇ µµÀÔ - ÇöÀçÀÇ °úÁ¦ ±Øº¹°ú ÇâÈÄ °èȹ
- Scott Wheelwright, PhD - Co-Founder and President, BEI
15:00 - 15:3030ÝÂ
Achievements in Intensified, Continuous, and Sustainable Bioprocessing
°È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
°È¡¤¿¬¼Ó¡¤Áö¼Ó°¡´É ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì¿¡¼ÀÇ ¼º°ú
Scientific Track Presentation
°úÇÐ Æ®·¢ ÇÁ·¹Á¨Å×À̼Ç
°úÇÐ Æ®·¢ ÇÁ·¹Á¨Å×À̼Ç
15:00 - 15:3030ÝÂ
Regulatory & CMC Strategies for Emerging Modalities
½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
½Å±Ô ¸ð´Þ¸®Æ¼ÀÇ ±ÔÁ¦¿Í CMC Àü·«
Scientific Track Presentation
°úÇÐ Æ®·¢ ÇÁ·¹Á¨Å×À̼Ç
°úÇÐ Æ®·¢ ÇÁ·¹Á¨Å×À̼Ç
15:30 - 16:0030ÝÂ
Networking Refreshment Break in Poster/Exhibit Hall
Æ÷½ºÅÍ/Àü½ÃȦ ³×Æ®¿öÅ· ¸®ÇÁ·¹½Ã ºê·¹ÀÌÅ©
Æ÷½ºÅÍ/Àü½ÃȦ ³×Æ®¿öÅ· ¸®ÇÁ·¹½Ã ºê·¹ÀÌÅ©
16:00 - 16:3030ÝÂ
Next Generation Bioprocessing, Digitalisation and Facilities of the Future
Â÷¼¼´ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì, µðÁöÅÐÈ, ¹Ì·¡ÀÇ ½Ã¼³
Â÷¼¼´ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì, µðÁöÅÐÈ, ¹Ì·¡ÀÇ ½Ã¼³
Establishing Flexible, Fully Disposable GMP Facility
À¯¿¬ÇÏ°í ¿ÏÀüÇÑ ÀÏȸ¿ë GMP ½Ã¼³ÀÇ ±¸Ãà
À¯¿¬ÇÏ°í ¿ÏÀüÇÑ ÀÏȸ¿ë GMP ½Ã¼³ÀÇ ±¸Ãà
16:00 - 16:3030ÝÂ
Upstream and Downstream Case Studies for Emerging Modalities
½Å±Ô ¸ð´Þ¸®Æ¼¿ë ¾÷½ºÆ®¸²¡¤´Ù¿î½ºÆ®¸² »ç·Ê ¿¬±¸
½Å±Ô ¸ð´Þ¸®Æ¼¿ë ¾÷½ºÆ®¸²¡¤´Ù¿î½ºÆ®¸² »ç·Ê ¿¬±¸
Process Automation with AI Technology for Cell Therapies
¼¼Æ÷Ä¡·á¿ë AI ±â¼ú¿¡ ÀÇÇÑ ÇÁ·Î¼¼½º ÀÚµ¿È
¼¼Æ÷Ä¡·á¿ë AI ±â¼ú¿¡ ÀÇÇÑ ÇÁ·Î¼¼½º ÀÚµ¿È
- Yasuhiro Takagi - Senior Director, Astellas Pharma Inc., Japan
16:30 - 17:0030ÝÂ
Next Generation Bioprocessing, Digitalisation and Facilities of the Future
Â÷¼¼´ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì, µðÁöÅÐÈ, ¹Ì·¡ÀÇ ½Ã¼³
Â÷¼¼´ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì, µðÁöÅÐÈ, ¹Ì·¡ÀÇ ½Ã¼³
Designing High Productivity, Cost Effective Modular Bioprocessing Facilities - Successes and Lessons Learned
°í»ý»ê¼º¡¤ºñ¿ë È¿À²Àû ¸ðµâ·¯ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½Ã¼³ÀÇ ¼³°è - ¼º°ø »ç·Ê¿Í ±³ÈÆ
°í»ý»ê¼º¡¤ºñ¿ë È¿À²Àû ¸ðµâ·¯ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì ½Ã¼³ÀÇ ¼³°è - ¼º°ø »ç·Ê¿Í ±³ÈÆ
16:30 - 17:0030ÝÂ
Upstream and Downstream Case Studies for Emerging Modalities
½Å±Ô ¸ð´Þ¸®Æ¼¿ë ¾÷½ºÆ®¸²¡¤´Ù¿î½ºÆ®¸² »ç·Ê ¿¬±¸
½Å±Ô ¸ð´Þ¸®Æ¼¿ë ¾÷½ºÆ®¸²¡¤´Ù¿î½ºÆ®¸² »ç·Ê ¿¬±¸
Utilizing Semi-Automated, Intensified Processes for Allogeneic Cell Therapies
µ¿Á¾ ¼¼Æ÷Ä¡·á¿ë ¹ÝÀÚµ¿¡¤°È ÇÁ·Î¼¼½ºÀÇ È°¿ë
µ¿Á¾ ¼¼Æ÷Ä¡·á¿ë ¹ÝÀÚµ¿¡¤°È ÇÁ·Î¼¼½ºÀÇ È°¿ë
17:00 - 17:3030ÝÂ
Next Generation Bioprocessing, Digitalisation and Facilities of the Future
Â÷¼¼´ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì, µðÁöÅÐÈ, ¹Ì·¡ÀÇ ½Ã¼³
Â÷¼¼´ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì, µðÁöÅÐÈ, ¹Ì·¡ÀÇ ½Ã¼³
Global Strategies for Operating in an Evolving Landscape - Next Generation Bioprocessing, Digitalisation and Facilities of the Future
ÁøÈÇÏ´Â »óȲ¿¡¼ ±â´ÉÇÏ´Â ±Û·Î¹ú Àü·« - Â÷¼¼´ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì, µðÁöÅÐÈ, ¹Ì·¡ÀÇ ½Ã¼³
ÁøÈÇÏ´Â »óȲ¿¡¼ ±â´ÉÇÏ´Â ±Û·Î¹ú Àü·« - Â÷¼¼´ë ¹ÙÀÌ¿ÀÇÁ·Î¼¼½Ì, µðÁöÅÐÈ, ¹Ì·¡ÀÇ ½Ã¼³
- Daisuke Kajihara - Senior Director of Bioprocess Technology Research Laboratories, Daiichi Sankyo Co., Ltd., Japan
17:00 - 17:3030ÝÂ
Upstream and Downstream Case Studies for Emerging Modalities
½Å±Ô ¸ð´Þ¸®Æ¼¿ë ¾÷½ºÆ®¸²¡¤´Ù¿î½ºÆ®¸² »ç·Ê ¿¬±¸
½Å±Ô ¸ð´Þ¸®Æ¼¿ë ¾÷½ºÆ®¸²¡¤´Ù¿î½ºÆ®¸² »ç·Ê ¿¬±¸
Benefits and Challenges of Adopting Novel Platforms to Intensify Processes and Ensure Quality in Next-Generation Biologics Manufacturing
Â÷¼¼´ë ¹ÙÀÌ¿À·ÎÁ÷½º Á¦Á¶¿¡¼ ÇÁ·Î¼¼½º °È¿Í ǰÁú È®º¸¿¡ ´ëÇÑ ½Å±Ô Ç÷§Æû µµÀÔÀÇ ÀÌÁ¡°ú °úÁ¦
Â÷¼¼´ë ¹ÙÀÌ¿À·ÎÁ÷½º Á¦Á¶¿¡¼ ÇÁ·Î¼¼½º °È¿Í ǰÁú È®º¸¿¡ ´ëÇÑ ½Å±Ô Ç÷§Æû µµÀÔÀÇ ÀÌÁ¡°ú °úÁ¦
17:30 - 17:355ÝÂ
Close of BPI Asia 2025
BPI Asia 2025 Æóȸ
BPI Asia 2025 Æóȸ
*½Å±Ô ¸ð´Þ¸®Æ¼¿ë ¾÷½ºÆ®¸²¡¤´Ù¿î½ºÆ®¸² »ç·Ê ¿¬±¸